Tourmaline Bio (TRML) Competitors $20.65 +0.31 (+1.52%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TRML vs. NAMS, IDYA, CNTA, RXRX, APGE, IBRX, WVE, MIRM, AKRO, and TARSShould you be buying Tourmaline Bio stock or one of its competitors? The main competitors of Tourmaline Bio include NewAmsterdam Pharma (NAMS), IDEAYA Biosciences (IDYA), Centessa Pharmaceuticals (CNTA), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), ImmunityBio (IBRX), Wave Life Sciences (WVE), Mirum Pharmaceuticals (MIRM), Akero Therapeutics (AKRO), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry. Tourmaline Bio vs. NewAmsterdam Pharma IDEAYA Biosciences Centessa Pharmaceuticals Recursion Pharmaceuticals Apogee Therapeutics ImmunityBio Wave Life Sciences Mirum Pharmaceuticals Akero Therapeutics Tarsus Pharmaceuticals NewAmsterdam Pharma (NASDAQ:NAMS) and Tourmaline Bio (NASDAQ:TRML) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings. Does the media refer more to NAMS or TRML? In the previous week, NewAmsterdam Pharma had 14 more articles in the media than Tourmaline Bio. MarketBeat recorded 18 mentions for NewAmsterdam Pharma and 4 mentions for Tourmaline Bio. Tourmaline Bio's average media sentiment score of 0.89 beat NewAmsterdam Pharma's score of 0.77 indicating that Tourmaline Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tourmaline Bio 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, NAMS or TRML? NewAmsterdam Pharma has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.32, indicating that its share price is 132% more volatile than the S&P 500. Do analysts prefer NAMS or TRML? NewAmsterdam Pharma currently has a consensus target price of $36.20, indicating a potential upside of 41.96%. Tourmaline Bio has a consensus target price of $54.00, indicating a potential upside of 161.50%. Given Tourmaline Bio's higher possible upside, analysts clearly believe Tourmaline Bio is more favorable than NewAmsterdam Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Tourmaline Bio 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer NAMS or TRML? NewAmsterdam Pharma received 4 more outperform votes than Tourmaline Bio when rated by MarketBeat users. CompanyUnderperformOutperformNewAmsterdam PharmaOutperform Votes21100.00% Underperform VotesNo VotesTourmaline BioOutperform Votes17100.00% Underperform VotesNo Votes Is NAMS or TRML more profitable? NewAmsterdam Pharma's return on equity of 0.00% beat Tourmaline Bio's return on equity.Company Net Margins Return on Equity Return on Assets NewAmsterdam PharmaN/A N/A N/A Tourmaline Bio N/A -20.97%-20.56% Which has preferable earnings & valuation, NAMS or TRML? Tourmaline Bio has lower revenue, but higher earnings than NewAmsterdam Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$33.59M70.13-$176.94MN/AN/ATourmaline BioN/AN/A-$42.12M-$2.82-7.32 Do insiders & institutionals have more ownership in NAMS or TRML? 89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are held by institutional investors. 19.5% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 11.0% of Tourmaline Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryNewAmsterdam Pharma beats Tourmaline Bio on 6 of the 11 factors compared between the two stocks. Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRML vs. The Competition Export to ExcelMetricTourmaline BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$529.53M$2.94B$5.13B$9.07BDividend YieldN/A1.90%5.08%4.23%P/E Ratio-7.3246.7389.5817.17Price / SalesN/A415.011,116.12116.95Price / CashN/A182.1042.8237.86Price / Book2.053.894.774.78Net Income-$42.12M-$42.21M$120.15M$225.60M7 Day Performance-5.32%-2.15%-1.92%-1.23%1 Month Performance-9.23%4.20%11.47%3.36%1 Year Performance2.58%18.39%30.52%16.60% Tourmaline Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRMLTourmaline Bio2.4402 of 5 stars$20.65+1.5%$54.00+161.5%+8.7%$529.53MN/A-7.3244High Trading VolumeNAMSNewAmsterdam Pharma2.8078 of 5 stars$24.50-0.8%$36.20+47.8%+142.4%$2.26B$33.59M0.0057Insider TradeAnalyst RevisionGap DownIDYAIDEAYA Biosciences4.3228 of 5 stars$25.95+3.0%$53.67+106.8%-23.7%$2.24B$3.92M-10.8180Analyst ForecastCNTACentessa Pharmaceuticals2.9997 of 5 stars$16.38-1.1%$25.83+57.7%+131.0%$2.16B$6.85M-10.8372Insider TradeRXRXRecursion Pharmaceuticals2.4151 of 5 stars$7.46+7.3%$9.25+24.0%-36.3%$2.14B$44.58M-4.85400News CoverageHigh Trading VolumeAPGEApogee Therapeutics2.5994 of 5 stars$46.81+5.2%$83.88+79.2%+92.5%$2.11BN/A-18.3991IBRXImmunityBio2.1332 of 5 stars$3.01+4.9%$17.38+477.2%-42.2%$2.10B$7.33M-3.36590Analyst ForecastWVEWave Life Sciences4.8841 of 5 stars$13.56+0.9%$22.22+63.9%+181.5%$2.07B$113.31M-12.11240Positive NewsMIRMMirum Pharmaceuticals4.0869 of 5 stars$42.32-0.3%$57.73+36.4%+34.8%$2.03B$307.03M-21.01140Positive NewsAKROAkero Therapeutics4.0824 of 5 stars$29.02+0.4%$46.83+61.4%+36.1%$2.03BN/A-7.7030Insider TradeTARSTarsus Pharmaceuticals0.3253 of 5 stars$51.58-1.8%$54.20+5.1%+164.4%$1.97B$17.45M-13.7850Positive News Related Companies and Tools Related Companies NewAmsterdam Pharma Alternatives IDEAYA Biosciences Alternatives Centessa Pharmaceuticals Alternatives Recursion Pharmaceuticals Alternatives Apogee Therapeutics Alternatives ImmunityBio Alternatives Wave Life Sciences Alternatives Mirum Pharmaceuticals Alternatives Akero Therapeutics Alternatives Tarsus Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TRML) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tourmaline Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRML Stock Alerts